SCHEMBL17748893

SCHEMBL17748893

COC(=O)c1ccc(-c2cn(C)c(=O)c3[nH]ccc23)cc1

nearest known ligand 0.71

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ BRD9 Q9H8M2 3/20 0.71
▸ CECR2 Q9BXF3 6/20 0.70
▸ BRD4 O60885 11/20 0.66
▸ TAF1 P21675 3/20 0.62
▸ TRIM24 O15164 1/20 0.57
▸ SMARCA2 P51531 1/20 0.57
▸ SMARCA4 P51532 1/20 0.57
▸ BRPF1 P55201 1/20 0.57
▸ EP300 Q09472 1/20 0.57
▸ PBRM1 Q86U86 1/20 0.57
▸ CREBBP Q92793 1/20 0.57
▸ BAZ2B Q9UIF8 1/20 0.57
▸ BAZ2A Q9UIF9 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17748890 0.86 CECR2 (0.75) BRD9CECR2BRD4TAF1TRIM24
SCHEMBL17748935 0.83 BRD9 (1.00) BRD9CECR2BRD4TAF1
SCHEMBL17748906 0.82 CECR2 (1.00) BRD9CECR2BRD4TAF1TRIM24
SCHEMBL31589682 0.82 BRD4 (0.70) BRD9CECR2BRD4
SCHEMBL17748929 0.80 CECR2 (1.00) BRD9CECR2BRD4TAF1TRIM24
SCHEMBL17748892 0.80 CECR2 (0.73) BRD9CECR2BRD4TAF1
SCHEMBL24866050 0.80 BRD4 (0.76) BRD9CECR2BRD4TAF1
SCHEMBL17748899 0.80 BRD4 (1.00) BRD9CECR2BRD4TAF1TRIM24
SCHEMBL19869924 0.80 BRD4 (0.95) BRD9CECR2BRD4TAF1TRIM24
SCHEMBL17748888 0.79 BRD4 (1.00) BRD9CECR2BRD4TAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3218374-B1 SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN GENENTECH INC (US) 2021-12-29 — — EP disclosed
CN-107108614-B Substituted pyrrolopyridines as bromodomain inhibitors 基因泰克公司 2021-06-01 — — CN disclosed
US-10150767-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2018-12-11 — — US disclosed
US-20170342067-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 — — US disclosed
US-20170342067-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 — — US disclosed
EP-3218374-A1 SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN Genentech, Inc. (US) 2017-09-20 — — EP disclosed
WO-2016077380-A1 SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN GENENTECH, INC. (US) 2016-05-19 — — WO disclosed
WO-2016077380-A1 SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN GENENTECH, INC. (US) 2016-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342067-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF BRD4, BRDT, BRPF3 BRD9 12/4885CECR2 246/4885BRD4 1/4885
US-10150767-B2 Therapeutic compounds and uses thereof BRD4, BRDT, BRPF3 BRD9 12/4885CECR2 246/4885BRD4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback